NEWRON PHARMACEUTICALS SPA - WELL POSITIONED TO CONTINUE ADVANCING CLINICAL DEVELOPMENT OF EVENAMIDE THROUGH REMAINDER OF 2026 AND INTO 2027

Reuters · 1d ago

Please log in to view news